Pharma Stocks To: Buy 2017

: Gained over 700% after positive Phase 2 data for its epilepsy treatment, ganaxolone.

: Rose nearly 700% following a lucrative licensing deal with Novartis for its antibody gevokizumab. pharma stocks to buy 2017

For investors seeking stability and income, large-cap pharma stocks remained dominant through R&D investment and consistent payouts. : Gained over 700% after positive Phase 2

: A top pick for dividends (yielding ~4.2%) and growth, with shares rising 45% in 2017 driven by Humira and its cancer drug pipeline. pharma stocks to buy 2017